Aurinia Pharmaceuticals (NASDAQ:AUPH) Shares Gap Up – Still a Buy?

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $11.06, but opened at $11.61. Aurinia Pharmaceuticals shares last traded at $11.20, with a volume of 244,109 shares.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada lifted their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a research note on Friday, August 1st. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a research report on Wednesday, July 30th. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $13.00.

Aurinia Pharmaceuticals Stock Up 0.9%

The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The firm has a market cap of $1.47 billion, a PE ratio of 25.97 and a beta of 1.26. The business has a fifty day moving average price of $11.66 and a two-hundred day moving average price of $9.34.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million for the quarter, compared to analysts’ expectations of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In other news, Director Kevin Tang purchased 200,000 shares of the stock in a transaction that occurred on Tuesday, August 5th. The stock was acquired at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the purchase, the director owned 11,329,500 shares in the company, valued at $132,328,560. This represents a 1.80% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders purchased 1,300,000 shares of company stock valued at $13,590,000. Insiders own 12.20% of the company’s stock.

Institutional Trading of Aurinia Pharmaceuticals

Large investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in Aurinia Pharmaceuticals by 56.1% during the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth $39,000. USA Financial Formulas bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $50,000. DekaBank Deutsche Girozentrale bought a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $60,000. Finally, Xponance Inc. bought a new stake in Aurinia Pharmaceuticals during the 1st quarter valued at approximately $82,000. Institutional investors own 36.83% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.